The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

serum AKR1B10 levels: Investigators collected blood from the patients every three months to test their serum AKR1B10 levels.

Study summary

Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, novel tumor biomarkers such as AKR1B10 (Aldo-keto reductase family 1 member B10) have been examined. This multicenter prospective cohort study aims to validate the predictive value of serum AKR1B10 for malignant transformation in cirrhosis-HCC progression, and evaluate its combined efficacy with existing risk prediction models, ultimately establishing a high-sensitivity early diagnostic strategy for clinical implementation.

Eligibility

Primary outcome measure(s)

• HCC — 36 mouths
  In this clinical trial, all patients with cirrhosis underwent ultrasound and serum AKR1B10 tests every three months

Trial sites (1)

More The First Affiliated Hospital of University of South China trials in China

Other trials for the same condition